Personal clinical trial finder

The information presented in the Myeloma Canada Personalized Clinical Trials Search Tool is from the International Clinical Trials database at ClinicalTrials.gov, indexed by the U.S. National Library of Medicine. Although the menu is in French, the details of the studies are only available in English.

Princess Margaret Cancer Centre clinical trials

Your search criteria - 48 result(s)

Print this list

POSTED : 2008-12-01 | START DATE : 2008-11-27 | LAST UPDATE : 2015-07-23

Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1/Phase 2

Recruitment status: Recruiting

Nearest centres:

The Ottawa Hospital, Ottawa, Ontario – Recruiting

POSTED : | START DATE : 2009-05-09 | LAST UPDATE : 2024-11-26

Collection of Tissue Samples for Cancer Research

Condition: Multiple MyelomaMyelodysplastic Syndromes

Study phase:

Recruitment status: Recruiting

Nearest centres:

Princess Margaret Hospital Cancer Centre, Toronto, – Completed

POSTED : | START DATE : 2013-04-19 | LAST UPDATE : 2024-12-05

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase:

Recruitment status: Recruiting

Nearest centres:

Local Institution - 0065, Toronto, Ontario – Withdrawn

Local Institute, Toronto, Ontario – Recruiting

Local Institution - 0066, Toronto, Ontario – Completed

Other Centres

Local Institute, Weston, Ontario – Recruiting

POSTED : | START DATE : 2015-01-13 | LAST UPDATE : 2024-09-12

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1/Phase 2

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Center/Alberta Health Services, Calgary, Alberta – Withdrawn

Cross Cancer Institute / University of Alberta, Edmonton, Alberta – Withdrawn

Vancouver General Hospital, Vancouver, British Columbia – Withdrawn

Other Centres

Cancer Care Manitoba, Winnipeg, Manitoba – (active not recruiting)

Memorial Hospital of Newfoundland, St. John's, Newfoundland and Labrador – Completed

Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia – Recruiting

Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

Maisonneuve-Rosemont Hospital, Montreal, Quebec – Completed

Royal Victoria Hospital / McGill University, Montreal, Quebec – Completed

POSTED : | START DATE : 2017-09-05 | LAST UPDATE : 2024-11-18

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1

Recruitment status: Recruiting

Nearest centres:

University of Calgary, Calgary, Alberta – Recruiting

Princess Margaret Cancer Center, Toronto, Ontario – Recruiting

Jewish General Hospital, Montreal, Quebec – Recruiting

POSTED : | START DATE : 2017-09-27 | LAST UPDATE : 2024-11-11

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Condition: Multiple MyelomaLymphoma, Non-Hodgkin

Study phase: Phase 2

Recruitment status: Recruiting

Nearest centres:

Cross Cancer Institute, Edmonton, Alberta – Recruiting

BCCA - Kelowna, Kelowna, British Columbia – Recruiting

BCCA - Vancouver, Vancouver, British Columbia – Recruiting

Other Centres

Kingston Health Sciences Centre, Kingston, Ontario – Recruiting

Verspeeten Family Cancer Centre, London, Ontario – Recruiting

Ottawa Hospital Research Institute, Ottawa, Ontario – Recruiting

University Health Network, Toronto, Ontario – Recruiting

The Jewish General Hospital, Montreal, Quebec – Recruiting

Allan Blair Cancer Centre, Regina, Saskatchewan – Recruiting

Saskatoon Cancer Centre, Saskatoon, Saskatchewan – Recruiting

POSTED : | START DATE : 2018-09-25 | LAST UPDATE : 2024-08-19

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

Condition: MeningiomaColorectal Neoplasms, Hereditary NonpolyposisUterine NeoplasmsHamartoma Syndrome, MultipleSyndrome

Study phase:

Recruitment status: Recruiting

Nearest centres:

Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

POSTED : 2019-07-18 | START DATE : 2019-04-24 | LAST UPDATE : 2020-03-27

Feasibility Study Comparing Enteral vs Parenteral Nutritional Outcomes in Autologous Stem Cell Transplant Patients

Condition: Hematologic Neoplasms

Study phase: N/A

Recruitment status: Recruiting

Nearest centres:

London Health Sciences Centre-Victoria Hospital, London, Ontario – Recruiting

POSTED : | START DATE : 2019-08-07 | LAST UPDATE : 2024-08-21

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

BCCA-Vancouver Cancer Centre, Vancouver, British Columbia – Recruiting

Atlantic Health Sciences Corporation-Saint John Regional Hospital, Saint John, New Brunswick – Recruiting

Kingston Health Sciences Centre, Kingston, Ontario – Recruiting

Other Centres

Lakeridge Health Oshawa, Oshawa, Ontario – Recruiting

Saint Michael's Hospital, Toronto, Ontario – Recruiting

POSTED : 2019-09-16 | START DATE : 2019-09-13 | LAST UPDATE : 2024-05-17

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1

Recruitment status: Recruiting

Nearest centres:

GSK Investigational Site, Edmonton, Alberta – Recruiting

GSK Investigational Site, London, Ontario – Completed

GSK Investigational Site, Ottawa, Ontario – Withdrawn

POSTED : | START DATE : 2020-02-10 | LAST UPDATE : 2024-10-04

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 2

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Centre, Calgary, Alberta – Recruiting

POSTED : | START DATE : 2021-07-07 | LAST UPDATE : 2025-01-10

A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1/Phase 2

Recruitment status: Recruiting

Nearest centres:

Cross Cancer Institute, Edmonton, Alberta – Recruiting

British Columbia Cancer Agency the Vancouver Centre, Vancouver, British Columbia – Recruiting

Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

Other Centres

Jewish General Hospital, Montreal, Quebec – Recruiting

POSTED : | START DATE : 2021-07-02 | LAST UPDATE : 2025-01-13

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Local Institution - 111, Calgary, Alberta – Completed

Local Institution - 103, Edmonton, Alberta – Completed

BC Cancer Agency, Fraser Valley Center, Surrey, British Columbia – Recruiting

Other Centres

Local Institution - 104, Saint John, New Brunswick – Completed

Memorial University of NewfoundlandDr. H Bliss Murphy Cancer Center, St John's, Newfoundland and Labrador – Recruiting

Queen Elizabeth Ii Health Sciences Centre, Halifax, Nova Scotia – Recruiting

Local Institution - 109, Ottawa, Quebec – Completed

Local Institution - 107, Saskatoon, Saskatchewan – Completed

CHU de Quebec-Universite Laval, Quebec, – Recruiting

POSTED : | START DATE : 2021-08-11 | LAST UPDATE : 2024-10-09

MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Center, Calgary, Alberta – (active not recruiting)

Cross Cancer Institute, Edmonton, Alberta – (active not recruiting)

QEII Health Sciences Centre - Victoria General Site, Halifax, Nova Scotia – (active not recruiting)

Other Centres

Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia – (active not recruiting)

Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario – (active not recruiting)

Princess Margaret Cancer Centre, Toronto, Ontario – (active not recruiting)

Jewish General Hospital, Montreal, Quebec – (active not recruiting)

CIUSSS de l'Est-de-l'Île-de-Montréal, Montréal, Quebec – (active not recruiting)

Saskatoon Cancer Center, Saskatoon, Saskatchewan – (active not recruiting)

POSTED : | START DATE : 2021-10-08 | LAST UPDATE : 2024-11-25

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 2

Recruitment status: Recruiting

Nearest centres:

Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta – Recruiting

Tom Baker Cancer Center, Calgary, Alberta – Recruiting

The Ottawa Hospital - General Campus, Ottawa, Ontario – Recruiting

Other Centres

Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

POSTED : | START DATE : 2021-12-07 | LAST UPDATE : 2024-07-30

Early Integration of Palliative and Supportive Care in Cellular Therapy

Condition: Multiple MyelomaHematologic Neoplasms

Study phase: N/A

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Centre, Calgary, Alberta – Recruiting

POSTED : | START DATE : 2022-01-27 | LAST UPDATE : 2025-01-14

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Cross Cancer Institute, Edmonton, – Recruiting

QEII Health Sciences Centre, Halifax, – Recruiting

The Ottawa General Hospital, Ottawa, – Recruiting

Other Centres

Saskatoon Cancer Center, Saskatoon, – Recruiting

"Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CIUSSS de l'Estrie - CHUS)", Sherbrooke, – Recruiting

Princess Margaret Cancer Centre, Toronto, – Recruiting

BC Cancer, Vancouver, – Recruiting

POSTED : | START DATE : 2022-02-16 | LAST UPDATE : 2025-01-21

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Center, Calgary, – Not yet recruiting

Cross Cancer Institute, Edmonton, – Recruiting

McMaster University, Hamilton, – Recruiting

Other Centres

Hopital Maisonneuve-Rosemont, Montréal, – Recruiting

Mcgill University Health Centre, Montréal, – Recruiting

Ottawa Hospital Research Institute, Ottawa, – Not yet recruiting

(CHU) Centre Hospitalier Universitaire de Quebec Laval, Québec, – Recruiting

Princess Margaret Cancer Centre, Toronto, – Recruiting

Vancouver General Hospital, Vancouver, – Recruiting

POSTED : | START DATE : 2022-02-14 | LAST UPDATE : 2024-12-09

Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 2

Recruitment status: Recruiting

Nearest centres:

London Health Sciences Centre, London, Ontario – Recruiting

POSTED : | START DATE : 2022-03-18 | LAST UPDATE : 2024-11-25

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta – Recruiting

Tom Baker Cancer Center, Calgary, Alberta – Recruiting

Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick – Recruiting

Other Centres

Saint John Regional Hospital, Saint John, New Brunswick – Recruiting

Hamilton Health Sciences Corporation, Hamilton, Ontario – Recruiting

Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

Windsor Regional Hospital Cancer Program, Windsor, Ontario – Recruiting

Centre Integre Universitaire de la Santé et de Services Sociaux de l'Est-de-l'ile-de-Montreal,, Montreal, Quebec – Recruiting

McGill University Health Centre, Montreal, Quebec – Recruiting

Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal (CIUSSS NÎ, Montreal, Quebec – Recruiting

POSTED : | START DATE : 2022-05-06 | LAST UPDATE : 2024-08-08

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1/Phase 2

Recruitment status: Recruiting

Nearest centres:

Alberta Health Services AHS - Foothills Medical Centre FMC, Calgary, Alberta – Recruiting

University of Alberta - Cross Cancer Institute, Edmonton, Alberta – Recruiting

University Health Network UHN - Princess Margaret Hospital PMH, Toronto, Ontario – Recruiting

POSTED : | START DATE : 2022-08-25 | LAST UPDATE : 2025-01-16

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre, Greenfield Park, Quebec – Recruiting

Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal (CIUSSS NÎM) - Hôpital du Sacré-Coeur, Montreal, Quebec – Recruiting

Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus, Quebec City, Quebec – Recruiting

POSTED : | START DATE : 2022-09-21 | LAST UPDATE : 2025-01-09

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta – Recruiting

Cross Cancer Institute, Edmonton, Alberta – Recruiting

British Columbia Cancer Agency, Vancouver, British Columbia – Recruiting

Other Centres

CHU de Quebec L Hotel Dieu de Quebec, Quebec, – Recruiting

POSTED : | START DATE : 2022-09-21 | LAST UPDATE : 2025-01-16

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

QEII Health Sciences Centre - Victoria General Site, Halifax, Nova Scotia – Recruiting

Victoria Hospital & Children's Hospital - London Health Sciences Centre, London, Ontario – Recruiting

Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

Other Centres

Local Institution - 0186, Montreal, Quebec – Withdrawn

POSTED : | START DATE : 2022-10-05 | LAST UPDATE : 2025-01-09

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta – Recruiting

Saint John Regional Hospital, Saint John, New Brunswick – Completed

Brampton Civic Hospital, Brampton, Ontario – Completed

Other Centres

Lakeridge Health Oshawa, Oshawa, Ontario – Recruiting

CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont, Montreal, Quebec – Recruiting

POSTED : | START DATE : 2022-10-26 | LAST UPDATE : 2024-11-11

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, Lenalidomide or Elranatamab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

QEII Health Sciences Centre, Halifax, Nova Scotia – Recruiting

Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

POSTED : 2022-12-09 | START DATE : 2022-11-30 | LAST UPDATE : 2024-06-04

LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study

Condition: Multiple Myeloma

Study phase:

Recruitment status: Recruiting

Nearest centres:

Edith Pituskin, Edmonton, Alberta – Recruiting

POSTED : | START DATE : 2022-12-06 | LAST UPDATE : 2025-01-06

A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1

Recruitment status: Recruiting

Nearest centres:

Juravinski Cancer Centre /ID# 252053, Hamilton, Ontario – Recruiting

Ottawa Hospital Research Institute /ID# 252151, Ottawa, Ontario – Recruiting

POSTED : | START DATE : 2022-12-01 | LAST UPDATE : 2024-12-11

A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1

Recruitment status: Recruiting

Nearest centres:

University Health Network (UHN) - Princess Margaret Cancer Centre (Princess Margaret Hospital), Toronto, Ontario – Recruiting

POSTED : | START DATE : 2023-02-06 | LAST UPDATE : 2025-01-08

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

The Ottawa Hospital, Ottawa, Ontario – Recruiting

University Health Network (UHN) - Princess Margaret Cancer Centre, Toronto, Ontario – Recruiting

Odette Sunnybrook Cancer Centre, Toronto, Ontario – Recruiting

POSTED : | START DATE : 2023-04-11 | LAST UPDATE : 2025-01-06

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Cross Cancer Institute, Edmonton, Alberta – Recruiting

The Ottawa Hospital - General Campus, Ottawa, Ontario – Recruiting

Jewish General Hospital, Montreal, Quebec – Recruiting

Other Centres

CHUQ - The Hôtel-Dieu de Québec, Quebec, – Recruiting

POSTED : 2023-09-28 | START DATE : 2023-09-05 | LAST UPDATE : 2024-06-17

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 4

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Center, Calgary, Alberta – Recruiting

Cross Cancer Institute, Edmonton, Alberta – Recruiting

McGill University Health Centre, Montréal, Quebec – Recruiting

POSTED : | START DATE : 2023-10-11 | LAST UPDATE : 2025-01-14

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1/Phase 2

Recruitment status: Recruiting

Nearest centres:

Research Site, Hamilton, Ontario – Recruiting

Research Site, Ottawa, Ontario – Recruiting

Research Site, Montreal, Quebec – Recruiting

POSTED : | START DATE : 2023-11-02 | LAST UPDATE : 2024-12-18

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Center, Calgary, Alberta – Recruiting

Local Institution - 0024, Toronto, Ontario – Not yet recruiting

POSTED : | START DATE : 2023-11-17 | LAST UPDATE : 2024-11-12

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

The Moncton Hospital, Moncton, New Brunswick – Recruiting

Jewish General Hospital, Montreal, Quebec – Recruiting

Centre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal (CIUSSS NÎ, Montreal, Quebec – Recruiting

POSTED : | START DATE : 2023-12-13 | LAST UPDATE : 2025-01-13

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

BCCA - Kelowna, Kelowna, British Columbia – Recruiting

BCCA - Vancouver, Vancouver, British Columbia – Not yet recruiting

CancerCare Manitoba, Winnipeg, Manitoba – Recruiting

Other Centres

The Moncton Hospital, Moncton, New Brunswick – Recruiting

Regional Health Authority B, Zone 2, Saint John, New Brunswick – Recruiting

William Osler Health System, Brampton, Ontario – Recruiting

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario – Recruiting

Kingston Health Sciences Centre, Kingston, Ontario – Recruiting

Grand River Regional Cancer Centre, Kitchener, Ontario – Recruiting

Verspeeten Family Cancer Centre, London, Ontario – Recruiting

Stronach Regional Health Centre at Southlake, Newmarket, Ontario – Recruiting

Lakeridge Health Oshawa, Oshawa, Ontario – Recruiting

Ottawa Hospital Research Institute, Ottawa, Ontario – Recruiting

Algoma District Cancer Program, Sault Ste. Marie, Ontario – Recruiting

Niagara Health System, St. Catharines, Ontario – Recruiting

St. Michael's Hospital, Toronto, Ontario – Recruiting

St. Joseph's Health Centre, Toronto, Ontario – Recruiting

The Jewish General Hospital, Montreal, Quebec – Recruiting

Allan Blair Cancer Centre, Regina, Saskatchewan – Recruiting

Saskatoon Cancer Centre, Saskatoon, Saskatchewan – Recruiting

POSTED : | START DATE : 2024-01-05 | LAST UPDATE : 2025-01-10

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta – Recruiting

British Columbia Cancer Agency, Vancouver, British Columbia – Recruiting

Nova Scotia Health Authority, Halifax, Nova Scotia – Recruiting

Other Centres

Juravinski Cancer Centre, Hamilton, Ontario – Recruiting

Princess Margaret Cancer Centre University Health Network, Toronto, Ontario – Recruiting

CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont, Montreal, Quebec – Recruiting

Saskatoon Cancer Centre, Saskatoon, Saskatchewan – Recruiting

POSTED : | START DATE : 2024-01-10 | LAST UPDATE : 2024-11-11

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1

Recruitment status: Recruiting

Nearest centres:

Dr. Everett Chalmers Regional Hospital, Fredericton, New Brunswick – Recruiting

CIUSSS de l'Est-de-l'Île-de-Montréal, Montreal, Quebec – Not yet recruiting

Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer, Sherbrooke, Quebec – Recruiting

POSTED : 2024-01-25 | START DATE : 2023-12-27 | LAST UPDATE : 2024-02-07

Preliminary Assessment of [18F]BL40 in PET/CT Scans

Condition: LymphomaMultiple MyelomaLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseWaldenstrom Macroglobulinemia

Study phase:

Recruitment status: Not yet recruiting

Nearest centres:

BC Cancer, Vancouver, British Columbia – ()

POSTED : | START DATE : 2024-02-19 | LAST UPDATE : 2024-09-09

Prehab Prior to Stem Cell Transplantation in Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: N/A

Recruitment status: Recruiting

Nearest centres:

University of Alberta/ Cross Cancer Institute, Edmonton, Alberta – Recruiting

POSTED : | START DATE : 2024-02-28 | LAST UPDATE : 2025-01-21

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 2

Recruitment status: Recruiting

Nearest centres:

Tom Baker Cancer Center, Calgary, Alberta – Recruiting

McGill University Health Centre, Montréal, Quebec – Recruiting

POSTED : 2024-05-03 | START DATE : 2024-05-01 | LAST UPDATE : 2024-05-01

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Recruiting

Nearest centres:

Local Institution - 0133, Edmonton, Alberta – Not yet recruiting

Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton, Ontario – Recruiting

Local Institution - 0134, Montreal, Quebec – Not yet recruiting

POSTED : | START DATE : 2024-03-11 | LAST UPDATE : 2024-10-16

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 2

Recruitment status: Not yet recruiting

Nearest centres:

Arnie Charbonneau Cancer Institute, Calgary, Alberta – ()

Cross Cancer Institute, Edmonton, Alberta – ()

Vancouver Cancer Center, Vancouver, British Columbia – ()

Other Centres

Juravinski Cancer Center, Hamilton, Ontario – ()

Ottawa Hospital, Ottawa, Ontario – ()

POSTED : | START DATE : 2024-05-17 | LAST UPDATE : 2025-01-09

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1

Recruitment status: Recruiting

Nearest centres:

Cross Cancer Institute, Edmonton, Alberta – Recruiting

Princess Margaret Cancer Centre University Health Network, Toronto, Ontario – Recruiting

POSTED : | START DATE : 2024-03-25 | LAST UPDATE : 2024-08-27

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

Condition: LymphomaMultiple MyelomaNeoplasms, Plasma CellLymphoma, B-CellAggression

Study phase: N/A

Recruitment status: Recruiting

Nearest centres:

Princess Margaret Cancer Centre, Toronto, – Recruiting

POSTED : | START DATE : 2024-09-18 | LAST UPDATE : 2025-01-08

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1

Recruitment status: Recruiting

Nearest centres:

Princess Margaret Hospital, Toronto, Ontario – Recruiting

POSTED : | START DATE : 2024-09-24 | LAST UPDATE : 2024-12-18

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 3

Recruitment status: Not yet recruiting

Nearest centres:

Local Institution - 0069, Calgary, Alberta – ()

Local Institution - 0003, Vancouver, British Columbia – ()

Local Institution - 0004, Halifax, Nova Scotia – ()

Other Centres

Local Institution - 0192, Hamilton, Ontario – ()

Local Institution - 0001, Montreal, Quebec – ()

POSTED : | START DATE : 2024-10-03 | LAST UPDATE : 2025-01-03

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

Condition: Multiple MyelomaNeoplasms, Plasma Cell

Study phase: Phase 1

Recruitment status: Recruiting

Nearest centres:

Investigational Site Number : 1240001, Montreal, Quebec – Recruiting